Zacks Investment Research downgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a hold rating to a sell rating in a report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Several other analysts also recently weighed in on OSMT. Wells Fargo & Co set a $14.00 price objective on shares of Osmotica Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, March 28th. Barclays reiterated a hold rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Osmotica Pharmaceuticals currently has an average rating of Buy and an average target price of $14.00.

Shares of NASDAQ:OSMT opened at $3.65 on Tuesday. The stock has a market cap of $205.57 million and a P/E ratio of -7.16. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.71. Osmotica Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $9.90. The business’s 50 day moving average is $3.09.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The firm had revenue of $57.13 million for the quarter, compared to analyst estimates of $53.58 million. As a group, equities research analysts expect that Osmotica Pharmaceuticals will post -0.25 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in OSMT. Great Point Partners LLC purchased a new stake in Osmotica Pharmaceuticals in the 4th quarter valued at $11,625,000. Sphera Funds Management LTD. purchased a new stake in Osmotica Pharmaceuticals in the 4th quarter valued at $7,147,000. Broadfin Capital LLC purchased a new stake in Osmotica Pharmaceuticals in the 4th quarter valued at $4,096,000. BlackRock Inc. purchased a new stake in Osmotica Pharmaceuticals in the 4th quarter valued at $3,682,000. Finally, Millennium Management LLC purchased a new stake in Osmotica Pharmaceuticals in the 4th quarter valued at $2,568,000. Hedge funds and other institutional investors own 11.64% of the company’s stock.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

See Also: Dead Cat Bounce

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.